Data from 2 large clinical trials showed new benefits of the dual sodium-glucose cotransporter 1 and 2 (SGLT1/SGLT2) inhibitor sotagliflozin for patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease as well as those with T2DM and recently worsening heart failure (HF). Both trials were terminated early due to COVID-19-related loss of funding.
Prof. Deepak Bhatt (Brigham and Women’s Hospital, USA) presented results of the SOLOIST-WHF trial (NCT03521934) as well as the SCORED trial (NCT03315143), both of which tested sotagliflozin [1,2]. Results were simultaneously published in the New Engla...
If you have no account yet, please
Please login to read the full text of the article.
« Anti-CD19 CAR T-cell therapy in relapsed/refractory indolent NHL Next Article
CD58 aberrations limit durable responses to CD19 CAR T-cell therapy »
Table of Contents: AHA 2020
COVID-19 and Influenza
CVD Risk Reduction
Acute Coronary Syndrome
Coronary and Valve Disease
If you have no account yet, please register now.